Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT06132126 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06132126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
November 17, 2023
Completion date
June 28, 2024
Enrollment
66 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, type 2 diabetes mellitus